Immunology Therapeutics
•260 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (260)
%
| Company | Market Cap | Price |
|---|---|---|
|
Self-Immunization Protocol (SIP) candidates represent immunology/immune-oncology therapeutics.
|
$35.83M |
$0.09
-9.09%
|
|
Platform centers on immunology therapeutics via engineered cytokines, aligning with Immunology Therapeutics.
|
$35.75M |
$2.07
-0.48%
|
|
MAIT cell immunotherapy platform and broader immunology therapeutics.
|
$34.35M |
$4.39
-2.55%
|
|
IMG-007 is a monoclonal antibody targeting OX40 developed for immunology/inflammatory diseases, aligning with Immunology Therapeutics.
|
$32.01M |
$7.96
-2.21%
|
|
The company concentrates on immunology therapeutics (immunotherapy for cancer and LEAPS platform for immunomodulation).
|
$31.77M |
$10.47
+2.25%
|
|
Kezar's lead candidate zetomipzomib targets immune-mediated diseases (autoimmune hepatitis), aligning with Immunology Therapeutics.
|
$30.83M |
$4.22
-5.17%
|
|
CID-103 is a fully human anti-CD38 monoclonal antibody developed for autoimmune diseases and organ transplant rejection, placing CASI in the Immunology Therapeutics space.
|
$30.28M |
$1.98
-3.41%
|
|
The strategy centers on immunology/immune-oncology approaches; Leap focuses on therapies modulating the immune response in cancer.
|
$26.46M |
$0.64
-4.13%
|
|
Immunology therapeutics programs (e.g., ustekinumab/adalimumab biosimilars) are part of Rani’s pipeline.
|
$26.37M |
$0.46
-3.54%
|
|
Company's immunomodulatory approach targets inflammatory diseases, aligning with 'Immunology Therapeutics'.
|
$25.29M |
$1.15
-1.71%
|
|
The company's immunotherapies target immune-mediated diseases, fitting into Immunology Therapeutics.
|
$23.77M |
$2.06
-8.44%
|
|
Bee venom–based therapeutic for OA/MS pain aligns with Immunology Therapeutics.
|
$21.76M |
$1.88
+0.53%
|
|
CB2 receptor–targeted anti-inflammatory/analgesic profile supports Immunology Therapeutics.
|
$21.32M |
$1.26
-6.67%
|
|
Certepetide modulates immune components in the tumor microenvironment, aligning with Immunology Therapeutics.
|
$20.38M |
$2.37
|
|
EB06 (anti-CXCL10 monoclonal antibody) and EB05/EB07 (paridiprubart-host-directed therapeutics) and EB01 (daniluromer cream) are immunology/inflammatory disease therapeutics developed by Edesa, aligning with Immunology Therapeutics.
|
$20.23M |
$2.76
-4.17%
|
|
Immunology-focused therapeutics and immune-modulation in oncology.
|
$19.55M |
$1.16
-12.12%
|
|
Immunology Therapeutics captures SAB Biotherapeutics' focus on immune-modulating antibody therapies, including SAB-142 for Type 1 Diabetes.
|
$19.14M |
$2.06
+4.04%
|
|
Immunology therapeutics is directly relevant due to mavorixafor's CXCR4 antagonism to modulate immune cell mobilization.
|
$17.89M |
$3.09
-6.36%
|
|
Lead botanical drug Phyto-N targets inflammatory/immune-mediated diseases (ulcerative colitis, atopic dermatitis), aligning with Immunology Therapeutics.
|
$16.76M |
$0.70
-6.82%
|
|
RBS has immunomodulatory/immune-activating profiles, aligning with immunology therapeutics.
|
$16.11M |
$0.08
+0.93%
|
|
The pipeline includes immunology therapeutics and immune-oncology programs (e.g., IBIO-101).
|
$14.19M |
$0.81
-0.30%
|
|
Immunology Therapeutics category relevant to immuno-oncology assets.
|
$14.19M |
$11.26
-5.06%
|
|
FHAB-enabled immunology/immune-oncology therapies align with immunology therapeutics as a primary therapeutic focus.
|
$13.96M |
$4.41
-6.96%
|
|
Immunology therapeutics alignment through immuno-oncology approaches.
|
$11.43M |
$1.01
-4.72%
|
|
Bolt's portfolio centers on immune-modulating cancer therapies, fitting the Immunology Therapeutics category.
|
$11.12M |
$5.80
-1.60%
|
|
Darnatein's design-augmented biologics and immunology-focused degenerative-disease programs align with Immunology Therapeutics.
|
$10.69M |
$0.55
-9.02%
|
|
Phio's immuno-oncology and immune-activation strategies fit Immunology Therapeutics as a broader immune-focused modality.
|
$10.57M |
$2.20
-7.09%
|
|
Palisade Bio's lead candidate PALI-2108 is an immunomodulatory therapy targeting inflammatory bowel disease, aligning with Immunology Therapeutics.
|
$9.59M |
$2.00
-3.38%
|
|
Biomica’s microbiome-based therapeutics for human health (immunology-related therapeutics).
|
$8.76M |
$1.29
-3.01%
|
|
ImmCelz/AlloStem programs involve immunomodulation and immune-cell–based therapies, aligning with immunology therapeutics.
|
$8.61M |
$3.33
-4.31%
|
|
The company's immunotherapeutic approach (oncolytic/gene therapy with potential checkpoint inhibitor combinations) fits Immunology Therapeutics.
|
$8.44M |
$0.56
-7.43%
|
|
KIO-104 targets retinal inflammation via immunology-based mechanism (DHODH inhibition), aligning with Immunology Therapeutics.
|
$8.22M |
$2.70
-4.26%
|
|
Immunology therapeutics category reflecting immune-based cancer therapies.
|
$8.21M |
$0.35
|
|
Immunology therapeutics targeting inflammatory conditions (TH023, anti-TNF-α antibody delivery).
|
$7.93M |
$2.98
-7.45%
|
|
Lead asset is an immunology-focused therapeutic targeting autoimmune diseases (systemic lupus erythematosus and Sjogren's), aligning with Immunology Therapeutics.
|
$7.63M |
$1.40
-11.39%
|
|
MM-001 and MM-003 are interferon-based therapies (immunomodulatory) addressing HPV-related disease and respiratory viral infections.
|
$7.04M |
$0.04
-6.38%
|
|
Engages in immunology therapeutics through AI-driven vaccine design for cancer and infectious diseases, a core immunology-oriented modality.
|
$6.39M |
$5.90
-9.65%
|
|
Immunotherapy therapeutics and modalities (cancer and autoimmune applications) align with Immunology Therapeutics.
|
$6.35M |
$2.10
-7.08%
|
|
ALZN002 immunotherapy approach places the company within Immunology Therapeutics.
|
$6.31M |
$2.18
-5.63%
|
|
The therapy modulates immune cells to address hyperinflammation (cytokine storm), fitting Immunology Therapeutics as an immune-modulation modality.
|
$6.04M |
$0.57
-4.73%
|
|
The company targets immune-inflammatory diseases and oncology with immunology-focused therapeutics.
|
$5.84M |
$4.06
-10.77%
|
|
INT230-6.00's immune-activating effects align with immunology therapeutics and immune-oncology concepts.
|
$5.61M |
$0.30
-17.43%
|
|
Preclinical ETS2 inflammatory signaling data suggests potential in Immunology Therapeutics / inflammation.
|
$5.58M |
$0.75
-3.55%
|
|
VYNE focuses on immuno-inflammatory therapeutics (BET inhibitors) addressing inflammatory diseases, aligning with Biotech - Immunology Therapeutics.
|
$5.53M |
$0.33
+5.00%
|
|
IDR (dusquetide) modulates the innate immune system, placing Soligenix in Immunology Therapeutics.
|
$5.48M |
$1.68
-5.08%
|
|
Immunomodulatory strategy using cytokine-secreting iMSCs targets immune responses in cancer and autoimmune contexts, fitting Immunology Therapeutics.
|
$5.38M |
$1.29
-5.47%
|
|
IMNN-001 and PlaCCine are immunotherapeutic modalities, fitting Immunology Therapeutics.
|
$5.23M |
$5.37
-0.56%
|
|
These programs are immunology-based cancer therapies, i.e., immunology therapeutics.
|
$4.69M |
$12.40
-2.21%
|
|
Company aims to elicit robust anti-tumor immune responses through tumor microenvironment modulation, aligning with Immunology Therapeutics.
|
$4.11M |
$1.55
-1.90%
|
|
Bezisterim's mechanism involves inflammatory pathways (ERK/NFκB), aligning with Immunology Therapeutics as an inflammatory CNS target.
|
$3.40M |
$1.83
-8.50%
|
|
Piclidenoson targets inflammatory conditions (psoriasis), aligning with Immunology Therapeutics.
|
$2.66M |
$0.53
-7.02%
|
|
Ampligen's immunomodulatory mechanism and TME reprogramming align with immunology therapeutics.
|
$1.93M |
$2.52
-3.45%
|
|
Extracellular vesicle targeting and immune-modulatory implications place the Hemopurifier within Immunology Therapeutics concepts.
|
$1.79M |
$0.69
-5.90%
|
|
LP-310/LP-10 involve immunomodulatory tacrolimus formulations for mucosal inflammatory conditions, fitting Immunology Therapeutics.
|
$1.63M |
$0.64
+16.28%
|
|
Immunology therapeutics focus due to immune modulation approaches for autoimmune and inflammatory diseases.
|
$703985 |
$0.02
-41.18%
|
|
APTEVO's portfolio centers on immunology/immune-oncology therapeutics (bispecifics/checkpoint-engagers), fitting Immunology Therapeutics.
|
$636578 |
$1.57
-7.10%
|
|
REVB's Gemini platform targets innate immunity/inflammation, placing the company in Immunology Therapeutics.
|
$481898 |
$1.51
+1.00%
|
|
Pipeline includes autoimmune/inflammatory indications, aligning with Immunology Therapeutics.
|
$391060 |
$0.49
-7.89%
|
|
ZyVersa's approach targets inflammasome pathways, fitting Immunology Therapeutics as a core category.
|
$350558 |
$0.14
-2.50%
|
|
Immunology therapeutics focus corresponding to allergic inflammation and autoimmune indications.
|
$229298 |
$0.00
|
Showing page 3 of 3 (260 total stocks)
Loading industry metrics...
Loading comparison data...
